We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Novo and competitors such as Sanofi and Eli ... and which now outsells its biggest insulin product, Levemir, which saw its revenues decline in 2016. FDA insistence that companies must undertake ...

By Eshe Nelson Reporting from London Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

LISBON, Feb 5 (Reuters) - Novo Banco's planned initial public offering would be beneficial for the Portuguese banking sector, Bank of Portugal Governor Mario Centeno said on Wednesday, but he ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get into all the earnings and political news ...

After hours: 7:59:22 p.m. EST Loading Chart for NVO ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...